APOE and amyloidosis: It has been demonstrated that the liver tropism, for example in the case of Onpattro, approved in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) by siRNA, is based on the endogenous targeting mediated by ApoE [91].